PTN Earnings

PTN reported its earnings on 2025-11-13, showcasing a revenue of 8.88M against an estimate of , resulting in a 0% surprise. The EPS was 4.26, surpassing the expected 0 by 0%. The stock experienced a -2.17% price change on the earnings day and a 22.78% change over the next five days, reflecting market reactions to the results.

Following PTN's earnings announcement on 2025-11-13, the stock price moved by -2.17% on the day of the release. Over the subsequent five days, it saw a 22.78% change. Historically, PTN's stock price tends to shift by an average of 10.62% in the 10 days leading up to earnings and 2.69% in the 10 days following, providing insight into potential market.

For 2026/Q3, analysts estimate PTN's annual revenue to reach 16.67K, while the EPS is projected at -2.26. These estimates reflect recent revisions, with revenue estimates revised upward by 15.04% and EPS estimates revised downward by -33.32% over the past three months, indicating analyst expectation in the company's performance.

The correlation between PTN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2026 were revised upward by 15.04%, while EPS estimates moved revised downward by -33.32%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PTN's stock price typically moves by 10.62% in the 10 days before its earnings and 2.69% in the 10 days after. For the upcoming 2026/Q3 earnings, analysts expect an EPS of -2.26 and revenue of 16.67K.

The earnings call reveals mixed signals: while there are promising developments in obesity treatments and a significant cash increase from a public offering, the financial results show widening losses and lower other income. The Q&A highlights cautious optimism in drug development but lacks concrete timelines or efficacy data, which may concern investors. The absence of new partnerships or strong guidance further tempers enthusiasm. Given these factors, the stock is likely to remain stable in the short term, leading to a neutral prediction.